A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 280 participants.
Also called NCT05179876
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 280 participants
- Sponsor
- Registry
-
NCT05179876 -
2021-002297-11 -
2023-506791-27-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belarus, Belgium, Bulgaria, China, Hungary, Poland, Russia, South Africa, South Korea, Taiwan, Thailand, Ukraine, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT05179876. Non-randomized; no masking; primary purpose treatment. Start 2022-05-04 (actual); primary completion 2027-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
- Acronym
- PLATYPUS
- Condition
- Hypertension, Pulmonary
- Intervention (Drug)
- Macitentan
- Intervention (Drug)
- Selexipag
- Intervention (Drug)
- Macitentan/Tadalafil FDC
- Lead sponsor
- Actelion
Record details
- Record id
cardio:ct-nct05179876- Content hash
699a31407a9740155c89830848b109ae6dbe5e4c5fdf22b1137478e32889f5d0